<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468933</url>
  </required_header>
  <id_info>
    <org_study_id>1070390</org_study_id>
    <nct_id>NCT03468933</nct_id>
  </id_info>
  <brief_title>Fibrinolysis Compared to Thoracoscopy for Pleural Infection</brief_title>
  <official_title>Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease Therapy Versus Early Medical Thoracoscopy for Treatment of Pleural Infection: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized clinical trial is to compare two currently&#xD;
      accepted standard-of-care treatment strategies: Medical thoracoscopy as compared to&#xD;
      instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant&#xD;
      Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic effusion&#xD;
      (CPPE) in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Pleural infection (empyema or complex parapneumonic effusion (CPPE)) represents&#xD;
      one of the most common clinical diagnoses encountered in clinical practice in the United&#xD;
      States (US) It is associated with substantial morbidity and mortality despite advances in&#xD;
      medical diagnostic and therapeutic strategies.&#xD;
&#xD;
      Objective: Compare two standard of care treatments: TPA/DNase vs early medical Thoracoscopy&#xD;
&#xD;
      Methods: Investigators will conduct a prospective randomized clinical trial. Plan is to&#xD;
      enroll total of 32 patients and randomize those patients to either Medical Thoracoscopy group&#xD;
      or Fibrinolytic Therapy group.&#xD;
&#xD;
      Follow-up will be daily until hospital discharge and at 6 and 12 weeks in the outpatient&#xD;
      setting&#xD;
&#xD;
      Potential Outcome and Benefit: Determine best strategy for treating patients with pleural&#xD;
      infection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Hospital Stay After Intervention</measure>
    <time_frame>12 week follow up period</time_frame>
    <description>duration of hospital stay in days from time of procedure to discharge from hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospital Stay</measure>
    <time_frame>12 week follow up period</time_frame>
    <description>Total days spent in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Necessitating Intervention After the Assigned Treatment</measure>
    <time_frame>12 week follow up period</time_frame>
    <description>Need for surgical intervention (VATS, Open Thoracotomy) in any arm&#xD;
Need for additional chest tube and/or fibrinolytic therapy in the medical thoracoscopy arm due to treatment failure&#xD;
Need of additional chest tube or additional fibrinolytic doses in the fibrinolytic therapy arm due to treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 week follow up period</time_frame>
    <description>any Adverse events (pain, bleeding)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Hospital and 30-day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death of a patient while being hospitalized or up to 30 days after</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pleural Infection</condition>
  <condition>Empyema</condition>
  <condition>Pleural Diseases</condition>
  <condition>Parapneumonic Effusion</condition>
  <arm_group>
    <arm_group_label>Fibrinolytic therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Thoracoscopy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)</intervention_name>
    <description>Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
    <arm_group_label>Fibrinolytic therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medical Thoracoscopy</intervention_name>
    <description>Medical thoracoscopy will be performed as per standard protocols.</description>
    <arm_group_label>Medical Thoracoscopy group</arm_group_label>
    <other_name>Pleuroscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects &gt;18 years old with:&#xD;
&#xD;
        Evidence of empyema or complex parapneumonic effusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt;18 years Pregnancy Inability to give informed written consent Previous thoracic&#xD;
        surgery or thrombolytic therapy for pleural infection Medical thoracoscopy cannot be&#xD;
        performed within 48 hours Hemodynamic instability or severe hypoxemia Non corrected&#xD;
        coagulopathy Homogeneously echogenic effusion on pleural ultrasonography&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fayez Kheir, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane Medical Center Tulane University Section of Pulmonary DiseasesTulane University Section of Pulmonary Diseases</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <results_first_submitted>December 5, 2020</results_first_submitted>
  <results_first_submitted_qc>January 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University</investigator_affiliation>
    <investigator_full_name>Fayez Kheir,MD,MSc</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Empyema</mesh_term>
    <mesh_term>Pleural Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03468933/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03468933/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fibrinolytic Therapy Group</title>
          <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
        </group>
        <group group_id="P2">
          <title>Medical Thoracoscopy Group</title>
          <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fibrinolytic Therapy Group</title>
          <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
        </group>
        <group group_id="B2">
          <title>Medical Thoracoscopy Group</title>
          <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="49" upper_limit="65"/>
                    <measurement group_id="B2" value="65" lower_limit="62.5" upper_limit="72.5"/>
                    <measurement group_id="B3" value="64" lower_limit="54.5" upper_limit="69.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ultrasonographic estimated pleural effusion volume,Moderate</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of subjects with community acquired pleural infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Hospital Stay After Intervention</title>
        <description>duration of hospital stay in days from time of procedure to discharge from hospital.</description>
        <time_frame>12 week follow up period</time_frame>
        <population>All participants received one of the assigned intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrinolytic Therapy Group</title>
            <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
          </group>
          <group group_id="O2">
            <title>Medical Thoracoscopy Group</title>
            <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospital Stay After Intervention</title>
          <description>duration of hospital stay in days from time of procedure to discharge from hospital.</description>
          <population>All participants received one of the assigned intervention</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="5.5"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Hospital Stay</title>
        <description>Total days spent in the hospital</description>
        <time_frame>12 week follow up period</time_frame>
        <population>All participants received assigned intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrinolytic Therapy Group</title>
            <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
          </group>
          <group group_id="O2">
            <title>Medical Thoracoscopy Group</title>
            <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Length of Hospital Stay</title>
          <description>Total days spent in the hospital</description>
          <population>All participants received assigned intervention</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="8.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Necessitating Intervention After the Assigned Treatment</title>
        <description>Need for surgical intervention (VATS, Open Thoracotomy) in any arm&#xD;
Need for additional chest tube and/or fibrinolytic therapy in the medical thoracoscopy arm due to treatment failure&#xD;
Need of additional chest tube or additional fibrinolytic doses in the fibrinolytic therapy arm due to treatment failure</description>
        <time_frame>12 week follow up period</time_frame>
        <population>All participants received assigned intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrinolytic Therapy Group</title>
            <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
          </group>
          <group group_id="O2">
            <title>Medical Thoracoscopy Group</title>
            <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Necessitating Intervention After the Assigned Treatment</title>
          <description>Need for surgical intervention (VATS, Open Thoracotomy) in any arm&#xD;
Need for additional chest tube and/or fibrinolytic therapy in the medical thoracoscopy arm due to treatment failure&#xD;
Need of additional chest tube or additional fibrinolytic doses in the fibrinolytic therapy arm due to treatment failure</description>
          <population>All participants received assigned intervention</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>any Adverse events (pain, bleeding)</description>
        <time_frame>12 week follow up period</time_frame>
        <population>All participants received assigned intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrinolytic Therapy Group</title>
            <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
          </group>
          <group group_id="O2">
            <title>Medical Thoracoscopy Group</title>
            <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>any Adverse events (pain, bleeding)</description>
          <population>All participants received assigned intervention</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Hospital and 30-day Mortality</title>
        <description>Death of a patient while being hospitalized or up to 30 days after</description>
        <time_frame>30 days</time_frame>
        <population>All participants received assigned intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Fibrinolytic Therapy Group</title>
            <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
          </group>
          <group group_id="O2">
            <title>Medical Thoracoscopy Group</title>
            <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
          </group>
        </group_list>
        <measure>
          <title>In Hospital and 30-day Mortality</title>
          <description>Death of a patient while being hospitalized or up to 30 days after</description>
          <population>All participants received assigned intervention</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The perioperative period until hospital discharge, an average of 4 weeks per participant</time_frame>
      <desc>Definition of adverse event and/or serious adverse event, used to collect adverse event information does not differ from the clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fibrinolytic Therapy Group</title>
          <description>Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.&#xD;
tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase): Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose</description>
        </group>
        <group group_id="E2">
          <title>Medical Thoracoscopy Group</title>
          <description>Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.&#xD;
Medical Thoracoscopy: Medical thoracoscopy will be performed as per standard protocols.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <description>Hemothorax without hemodynamic instability and did not need transfusion, but was monitored in the intensive care unit overnight. Intraprocedural hypoxia that resolved with insertion of a supraglottic airway tube and oxygen therapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fayez Kheir</name_or_title>
      <organization>Tulane University</organization>
      <phone>504-988-3541</phone>
      <email>fkheir@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

